Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid

E. Giller, D. D. Bialos, L. Harkness, Mark A Riddle

Research output: Contribution to journalArticle

Abstract

The response to the MAOI isocarboxazid was investigated in a two-phase protocol. Phase 1 was a double-blind, placebo-controlled study; Phase 2 was an open active medication trial for Phase 1 placebo patients who still met symptom criteria. In Phase 1, 60 male outpatients were randomly divided into placebo or active medication groups. Mean platelet MAO inhibition was 86% by Week 1, while significant symptomatic improvement was not seen until Week 3. In Phase 2, 16 of the symptomatic placebo patients were given an open trial on isocarboxazid; thus, 43 patients received a trial of active medication. Separation of responders (N=26) from nonresponders (N=17) by discriminant function analysis using 3 entry variables (platelet MAO activity, standing diastolic blood pressure, and psychomotor irregularity) accounted for 28% of the variance, with correct classification of 32 of the 43 patients.

Original languageEnglish (US)
Pages (from-to)44-48
Number of pages5
JournalJournal of Clinical Psychiatry
Volume45
Issue number7 II
StatePublished - 1984
Externally publishedYes

Fingerprint

Isocarboxazid
Monoamine Oxidase Inhibitors
Placebos
Monoamine Oxidase
Blood Platelets
Blood Pressure
Discriminant Analysis
Therapeutics
Outpatients

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid. / Giller, E.; Bialos, D. D.; Harkness, L.; Riddle, Mark A.

In: Journal of Clinical Psychiatry, Vol. 45, No. 7 II, 1984, p. 44-48.

Research output: Contribution to journalArticle

Giller, E. ; Bialos, D. D. ; Harkness, L. ; Riddle, Mark A. / Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid. In: Journal of Clinical Psychiatry. 1984 ; Vol. 45, No. 7 II. pp. 44-48.
@article{3d788f0022a64b4b84fae271a67fa1f9,
title = "Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid",
abstract = "The response to the MAOI isocarboxazid was investigated in a two-phase protocol. Phase 1 was a double-blind, placebo-controlled study; Phase 2 was an open active medication trial for Phase 1 placebo patients who still met symptom criteria. In Phase 1, 60 male outpatients were randomly divided into placebo or active medication groups. Mean platelet MAO inhibition was 86{\%} by Week 1, while significant symptomatic improvement was not seen until Week 3. In Phase 2, 16 of the symptomatic placebo patients were given an open trial on isocarboxazid; thus, 43 patients received a trial of active medication. Separation of responders (N=26) from nonresponders (N=17) by discriminant function analysis using 3 entry variables (platelet MAO activity, standing diastolic blood pressure, and psychomotor irregularity) accounted for 28{\%} of the variance, with correct classification of 32 of the 43 patients.",
author = "E. Giller and Bialos, {D. D.} and L. Harkness and Riddle, {Mark A}",
year = "1984",
language = "English (US)",
volume = "45",
pages = "44--48",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "7 II",

}

TY - JOUR

T1 - Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid

AU - Giller, E.

AU - Bialos, D. D.

AU - Harkness, L.

AU - Riddle, Mark A

PY - 1984

Y1 - 1984

N2 - The response to the MAOI isocarboxazid was investigated in a two-phase protocol. Phase 1 was a double-blind, placebo-controlled study; Phase 2 was an open active medication trial for Phase 1 placebo patients who still met symptom criteria. In Phase 1, 60 male outpatients were randomly divided into placebo or active medication groups. Mean platelet MAO inhibition was 86% by Week 1, while significant symptomatic improvement was not seen until Week 3. In Phase 2, 16 of the symptomatic placebo patients were given an open trial on isocarboxazid; thus, 43 patients received a trial of active medication. Separation of responders (N=26) from nonresponders (N=17) by discriminant function analysis using 3 entry variables (platelet MAO activity, standing diastolic blood pressure, and psychomotor irregularity) accounted for 28% of the variance, with correct classification of 32 of the 43 patients.

AB - The response to the MAOI isocarboxazid was investigated in a two-phase protocol. Phase 1 was a double-blind, placebo-controlled study; Phase 2 was an open active medication trial for Phase 1 placebo patients who still met symptom criteria. In Phase 1, 60 male outpatients were randomly divided into placebo or active medication groups. Mean platelet MAO inhibition was 86% by Week 1, while significant symptomatic improvement was not seen until Week 3. In Phase 2, 16 of the symptomatic placebo patients were given an open trial on isocarboxazid; thus, 43 patients received a trial of active medication. Separation of responders (N=26) from nonresponders (N=17) by discriminant function analysis using 3 entry variables (platelet MAO activity, standing diastolic blood pressure, and psychomotor irregularity) accounted for 28% of the variance, with correct classification of 32 of the 43 patients.

UR - http://www.scopus.com/inward/record.url?scp=0021254721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021254721&partnerID=8YFLogxK

M3 - Article

C2 - 6376484

AN - SCOPUS:0021254721

VL - 45

SP - 44

EP - 48

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 7 II

ER -